Literature DB >> 23529766

Managing unexpected events in the manufacturing of biologic medicines.

Gustavo Grampp1, Sundar Ramanan.   

Abstract

The manufacturing of biologic medicines (biologics) requires robust process and facility design, rigorous regulatory compliance, and a well-trained workforce. Because of the complex attributes of biologics and their sensitivity to production and handling conditions, manufacturing of these medicines also requires a high-reliability manufacturing organization. As required by regulators, such an organization must monitor the state-of-control for the manufacturing process. A high-reliability organization also invests in an experienced and fully engaged technical support staff and fosters a management culture that rewards in-depth analysis of unexpected results, robust risk assessments, and timely and effective implementation of mitigation measures. Such a combination of infrastructure, technology, human capital, management, and a science-based operations culture does not occur without a strong organizational and financial commitment. These attributes of a high-reliability biologics manufacturer are difficult to achieve and may be differentiating factors as the supply of biologics diversifies in future years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529766     DOI: 10.1007/s40259-013-0018-5

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  3 in total

1.  High-Throughput Assessment of Structural Continuity in Biologics.

Authors:  Caterina Musetti; Mark F Bean; Geoffrey T Quinque; Christopher Kwiatkowski; Lawrence M Szewczuk; John Baldoni; Matthew A Zajac
Journal:  Anal Chem       Date:  2018-02-08       Impact factor: 6.986

2.  Manufacturing history of etanercept (Enbrel®): Consistency of product quality through major process revisions.

Authors:  Brian Hassett; Ena Singh; Ehab Mahgoub; Julie O'Brien; Steven M Vicik; Brian Fitzpatrick
Journal:  MAbs       Date:  2017-11-29       Impact factor: 5.857

Review 3.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.